<DOC>
	<DOC>NCT00937820</DOC>
	<brief_summary>The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.</brief_summary>
	<brief_title>Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<criteria>Subject has symptomatic VTE and/or asymptomatic deep vein thrombosis Written informed consent obtained before screening Subject has history of deep vein thrombosis and/or pulmonary embolism Subject has a hemorrhagic disorder and/or coagulation disorder Subject has had clinically important bleeding occurred within 90 days prior to the screening visit Subject has an acute bacterial endocarditis Subject has uncontrolled severe or moderate hypertension, retinopathy, myocardial infarction or stroke Subject is receiving anticoagulants/antiplatelet agents Subject has a body weight less than 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>YM150</keyword>
	<keyword>Bleeding</keyword>
	<keyword>VTE</keyword>
	<keyword>FXa inhibitor</keyword>
	<keyword>Venous thromboembolism</keyword>
</DOC>